CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 63 enrolled
Drug / intervention
Busulfan +2 moredrug
Likely dose
Busulfan 32 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00475020
NCT00475020Phase 2Completed
CompareCT.gov

Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome Using Reduced Intensity Busulfan and Fludarabine Conditioning

M.D. Anderson Cancer Center·interventional·Posted May 17, 2007·Updated May 21, 2019

In Brief

A Phase 2 clinical trial evaluating Busulfan, Fludarabine, and 1 other intervention for Myelofibrosis. Completed, enrolled 63 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if using a combination of fludarabine, busulfan, and antithymocyte globulin (ATG) can help to control myelofibrosis or myelodysplastic syndrome in patients receiving a bone marrow or blood stem cell transplant. The safety of these drugs will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyelofibrosis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 17, 2007
Enrollment StartJan 4, 2006
Primary CompletionOct 4, 2017
TodayJul 2, 2026
Enrollment to primary: 11.8 yearsPosted 19.1 years ago

Interventions

Busulfandrug

Test dose = 32 mg/m\^2 by vein x 1 day; 100 mg/m\^2 by vein daily over 3 hours x 4 days

Fludarabinedrug

40 mg/m\^2 by vein daily over 1 hour x 4 days

Thymoglobulin (ATG)drug

2.5 mg/kg by vein over 6 hours x 3 days if there is an unrelated or a mismatched donor